220 related articles for article (PubMed ID: 9363871)
1. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
Stadler WM; Kuzel T; Roth B; Raghavan D; Dorr FA
J Clin Oncol; 1997 Nov; 15(11):3394-8. PubMed ID: 9363871
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
Moore MJ; Tannock IF; Ernst DS; Huan S; Murray N
J Clin Oncol; 1997 Dec; 15(12):3441-5. PubMed ID: 9396395
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Galsky MD; Hahn NM; Powles T; Hellerstedt BA; Lerner SP; Gardner TA; Yu M; O'Rourke M; Vogelzang NJ; Kocs D; McKenney SA; Melnyk AM; Hutson TE; Rauch M; Wang Y; Asmar L; Sonpavde G
Clin Genitourin Cancer; 2013 Jun; 11(2):175-81. PubMed ID: 23228446
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
5. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
De Santis M; Bachner M; Cerveny M; Kametriser G; Steininger T; Königsberg R; Schratter-Sehn A; Sedlmayer F; Dittrich C
Ann Oncol; 2014 Sep; 25(9):1789-1794. PubMed ID: 24936582
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
von der Maase H; Lehmann J; Gravis G; Joensuu H; Geertsen PF; Gough J; Chen G; Kania M
Ann Oncol; 2006 Oct; 17(10):1533-8. PubMed ID: 16873433
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
8. Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.
Mermershtain W; Cohen AD; Lazarev I; Grunwald M; Ariad S
J Chemother; 2003 Oct; 15(5):510-1. PubMed ID: 14598945
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer.
Vogelzang NJ; Stadler WM
Urology; 1999 Feb; 53(2):243-50. PubMed ID: 9933034
[TBL] [Abstract][Full Text] [Related]
10. Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment.
Castagneto B; Zai S; Marenco D; Bertetto O; Repetto L; Scaltriti L; Mencoboni M; Ferraris V; Botta M
Oncology; 2004; 67(1):27-32. PubMed ID: 15459492
[TBL] [Abstract][Full Text] [Related]
11. [Gemcitabine in advanced bladder cancer].
Lehmann J; Retz M; Lippert C; Albers P; Stöckle M
Urologe A; 2003 Jan; 42(1):63-77. PubMed ID: 12574885
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G
Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232
[TBL] [Abstract][Full Text] [Related]
14. Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
Carles J; Suárez C; Mesía C; Nogué M; Font A; Doménech M; Suárez M; Tusquets I; Gallén M; Albanell J; Fabregat X
Clin Transl Oncol; 2006 Oct; 8(10):755-7. PubMed ID: 17074675
[TBL] [Abstract][Full Text] [Related]
15. [Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
Beardo Villar P; Gamaza Martínez R; Gavira Moreno R
Farm Hosp; 2014 May; 38(3):249-51. PubMed ID: 24951911
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ; Winquist EW; Murray N; Tannock IF; Huan S; Bennett K; Walsh W; Seymour L
J Clin Oncol; 1999 Sep; 17(9):2876-81. PubMed ID: 10561365
[TBL] [Abstract][Full Text] [Related]
17. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
Herman JM; Smith DC; Montie J; Hayman JA; Sullivan MA; Kent E; Griffith KA; Esper P; Sandler HM
Urology; 2004 Jul; 64(1):69-73. PubMed ID: 15245938
[TBL] [Abstract][Full Text] [Related]
18. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
von der Maase H; Andersen L; Crinò L; Weinknecht S; Dogliotti L
Ann Oncol; 1999 Dec; 10(12):1461-5. PubMed ID: 10643537
[TBL] [Abstract][Full Text] [Related]
19. Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study.
Gebbia V; Testa A; Borsellino N; Mauceri G; Varvara F; Tirrito ML; Sambataro D; Fallica G
Clin Ter; 1999; 150(1):11-5. PubMed ID: 10367539
[TBL] [Abstract][Full Text] [Related]
20. Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H
Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
